Integrated drug discovery panel – your questions answered!
ABOUT THIS WEBINAR
Drug Discovery from concept to drug candidate has become a collective effort where multi-disciplinary project teams from CRO’s work with drug companies and academia to deliver clinical candidates, overcoming multi-factorial research obstacles along the way.
Charles River has established an Integrated Drug Discovery team of experts with diverse backgrounds across multiple therapeutic areas whose sole purpose is to innovate, consult, and proactively solve problems on your discovery programs.
During this peer panel discussion, team members from Charles River discussed their views and strategies on Drug Discovery and gave their answers to your challenging questions.
John Montana, PhD, Corporate VP, Integrated Drug Development and Strategic Projects, Charles River
John’s long history of developing holistic research strategies, program oversight, and scientific progression from target validation to clinical trials for pharma and biotech companies has appeared in over 150 peer-reviewed papers and patents.
Alan Young, PhD, Senior Director In Vivo Respiratory and Inflammation, Integrated Drug Discovery, Charles River
A pharmacologist who has worked in respiratory research for over 25 years within the pharmaceutical industry leading multiple respiratory-based projects, and delivered more than 20 candidate drugs into clinical development.
Martin O’Rourke, PhD, Senior Director Oncology In Vitro Sciences, Integrated Drug Discovery, Charles River
For over 14 years Martin has worked in oncology research piloting projects across all aspects of drug discovery from target validation to candidate nomination through to translation of compounds from preclinical to the clinic.
Robert Hodgson, PhD, Director In Vivo CNS, Integrated Drug Discovery, Charles River
With expertise in behavioural pharmacology, PK/PD, in vitro-in vivo correlations, microdialysis and electrophysiology, Robert is immersed in drug discovery and passionate about advancement of novel therapies to treat CNS diseases.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!